CNS Drugs

, Volume 31, Issue 10, pp 891–898 | Cite as

Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany

  • Brendan J. Snellgrove
  • Tilman Steinert
  • Susanne Jaeger
Original Research Article



The antiepileptic drug pregabalin is one of the best-selling pharmaceutical products worldwide. There are increasing concerns about its potential for misuse and dependence especially among patients with former or current substance use disorders (SUDs).


Our objective was to clarify the extent and pattern of pregabalin use as well as motives and predictors in this population.


We conducted a cross-sectional study with patients on a detoxification ward for illicit drugs at the Center for Psychiatry, Südwürttemberg, Ravensburg in southern Germany from August 2012 until July 2013. We used an extensive questionnaire, part of the Structured Clinical Interview for DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition) Axis I Disorders (SCID-I) and urine samples.


Of the 253 participating patients, 56% had used pregabalin at least once. Of these, 92% had acquired it at least in part from illegal sources. The main motives for the use of pregabalin were the attenuation of opioid withdrawal symptoms, the augmentation of other psychotropic substances, and the psychotropic effects of pregabalin itself. Predictors for pregabalin use were opioid and sedative use as well as younger age. The criteria of dependency according to DSM-IV was met by 11% of pregabalin users and 13% of urine samples were positive for pregabalin.


Use of pregabalin is common among users of illicit drugs in large parts of southern Germany, with motives for use, acquisition, and mode of use suggesting misuse. The mode of use, especially intake of high doses and concomitant use of other drugs, poses a serious risk to this population, including the development of dependency.


Compliance with Ethical Standards

Ethics approval

The study was approved by the appropriate research ethics committee of the University of Ulm (Application no. 184/12).

Informed consent

Written informed consent was obtained from all participants included in the study.

Conflict of interest

Brendan J. Snellgrove, Tilman Steinert, and Susanne Jaeger declare that there are no conflicts of interest.


No specific funding was received for this study.


  1. 1.
    Fijalkowski L, Salat K, Podkowa A, Zareba P, Nowaczyk A. Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors-Molecular docking and pharmacodynamic studies. Eur J Pharm Sci. 2017;96:362–72. doi: 10.1016/j.ejps.2016.10.004.CrossRefPubMedGoogle Scholar
  2. 2.
    Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007;105:1805–15. doi: 10.1213/01.ane.0000287643.13410.5e.CrossRefPubMedGoogle Scholar
  3. 3.
    Freynhagen R, Backonja M, Schug S, Lyndon G, Parsons B, Watt S, et al. Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review. CNS Drugs. 2016;30:1191–200. doi: 10.1007/s40263-016-0390-z.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Evoy KE, Morrison MD, Saklad SR. Abuse and misuse of pregabalin and gabapentin. Drugs. 2017;77:403–26. doi: 10.1007/s40265-017-0700-x.CrossRefPubMedGoogle Scholar
  5. 5.
    Schjerning O, Rosenzweig M, Pottegard A, Damkier P, Nielsen J. Abuse potential of pregabalin: a systematic review. CNS Drugs. 2016;30:9–25. doi: 10.1007/s40263-015-0303-6.CrossRefPubMedGoogle Scholar
  6. 6.
    IMS Health HQ Limited. Top 20 global products 2015. 2015. Accessed 15 Sept 2017.
  7. 7.
    Wilens T, Zulauf C, Ryland D, Carrellas N, Catalina-Wellington I. Prescription medication misuse among opioid dependent patients seeking inpatient detoxification. Am J Addict. 2015;24:173–7. doi: 10.1111/ajad.12159.CrossRefPubMedGoogle Scholar
  8. 8.
    Baird CRW, Fox P, Colvin LA. Gabapentinoid abuse in order to potentiate the effect of methadone: a survey among substance misusers. Eur Addict Res. 2014;20:115–8. doi: 10.1159/000355268.CrossRefPubMedGoogle Scholar
  9. 9.
    Grosshans M, Lemenager T, Vollmert C, Kaemmerer N, Schreiner R, Mutschler J, et al. Pregabalin abuse among opiate addicted patients. Eur J Clin Pharmacol. 2013;69:2021–5. doi: 10.1007/s00228-013-1578-5.CrossRefPubMedGoogle Scholar
  10. 10.
    Abrahamsson T, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug Alcohol Depend. 2017;174:58–64. doi: 10.1016/j.drugalcdep.2017.01.013.CrossRefPubMedGoogle Scholar
  11. 11.
    Hakkinen M, Vuori E, Kalso E, Gergov M, Ojanpera I. Profiles of pregabalin and gabapentin abuse by postmortem toxicology. Forensic Sci Int. 2014;241:1–6. doi: 10.1016/j.forsciint.2014.04.028.CrossRefPubMedGoogle Scholar
  12. 12.
    Barrett SP, Meisner JR, Stewart SH. What constitutes prescription drug misuse? Problems and pitfalls of current conceptualizations. Curr Drug Abuse Rev. 2008;1:255–62.CrossRefPubMedGoogle Scholar
  13. 13.
    O’brien CP. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry. 2005;66(Suppl 2):28–33.Google Scholar
  14. 14.
    Portenoy RK. Opioid therapy for chronic nonmalignant pain: a review of the critical issues. J Pain Symptom Manag. 1996;11:203–17.CrossRefGoogle Scholar
  15. 15.
    Hoffmann F, Glaeske G. Benzodiazepine hypnotics, zolpidem and zopiclone on private prescriptions: use between 1993 and 2012. Nervenarzt. 2014;85:1402–9. doi: 10.1007/s00115-014-4016-8.CrossRefPubMedGoogle Scholar
  16. 16.
    Wittchen H-U, Wunderlich U, Gruschwitz S, Zaudig M. Strukturiertes Klinisches Interview für DSM-IV, Achse I: psychische Störungen, Interviewheft. Göttingen: Hogrefe; 1997.Google Scholar
  17. 17.
    Mutschler J, Gastberger S, Baumgartner MR, Grosshans M, Seifritz E, Quednow BB, Herdener M. Pregabalin use among opioid-addicted patients in Switzerland. J Clin Psychiatry. 2016;77:1202–3. doi: 10.4088/JCP.15l10296.CrossRefPubMedGoogle Scholar
  18. 18.
    Alblooshi H, Hulse GK, El Kashef A, Al Hashmi H, Shawky M, Al Ghaferi H, et al. The pattern of substance use disorder in the United Arab Emirates in 2015: results of a National Rehabilitation Centre cohort study. Subst Abuse Treat Prev Policy. 2016;11:19. doi: 10.1186/s13011-016-0062-5.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69:1335–42. doi: 10.1007/s00228-012-1464-6.CrossRefPubMedGoogle Scholar
  20. 20.
    Wittchen H-U, Bühringer G, Rehm JT, Soyka M, Träder A, Trautmann S. The Social, clinical and treatment situation of opioid maintenance treatment in a prevalence sample of patients at baseline. Suchtmed. 2011;13:227–31.Google Scholar
  21. 21.
    Schifano F, D’Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118–22. doi: 10.1159/000321079.CrossRefPubMedGoogle Scholar
  22. 22.
    Hasanein P, Shakeri S. Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats. Eur J Pharmacol. 2014;742:113–7. doi: 10.1016/j.ejphar.2014.08.030.CrossRefPubMedGoogle Scholar
  23. 23.
    Vashchinkina E, Piippo O, Vekovischeva O, Krupitsky E, Ilyuk R, Neznanov N, et al. Addiction-related interactions of pregabalin with morphine in mice and humans: reinforcing and inhibiting effects. Addict Biol. 2017. doi: 10.1111/adb.12538.Google Scholar
  24. 24.
    Kammerer N, Lemenager T, Grosshans M, Kiefer F, Hermann D. Pregabalin for the reduction of opiate withdrawal symptoms. Psychiatr Prax. 2012;39:351–2. doi: 10.1055/s-0032-1305042.CrossRefPubMedGoogle Scholar
  25. 25.
    Kapil V, Green JL, Le Lait M-C, Wood DM, Dargan PI. Misuse of the gamma-aminobutyric acid analogues baclofen, gabapentin and pregabalin in the UK. Br J Clin Pharmacol. 2014;78:190–1.CrossRefPubMedGoogle Scholar
  26. 26.
    Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs. 2014;28:491–6. doi: 10.1007/s40263-014-0164-4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Brendan J. Snellgrove
    • 1
    • 2
  • Tilman Steinert
    • 1
    • 2
  • Susanne Jaeger
    • 1
    • 2
  1. 1.Centre for Psychiatry South-WuerttembergRavensburgGermany
  2. 2.Department Psychiatry IUlm UniversityUlmGermany

Personalised recommendations